Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$77.07 USD

77.07
4,558,389

-0.62 (-0.80%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $77.28 +0.21 (0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

by Zacks Equity Research

Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

    Zacks Equity Research

    Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.

      Arpita Dutt headshot

      Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs

      by Arpita Dutt

      Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.

        Zacks Equity Research

        Ironwood (IRWD) Q4 Loss Narrower than Expected; Sales Top

        by Zacks Equity Research

        Ironwood Pharmaceuticals, Inc. (IRWD) reported an adjusted loss of 12 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 23 cents but slightly wider than the year-ago loss of 11 cents.

          Zacks Equity Research

          Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.

          by Zacks Equity Research

          Valeant Pharmaceuticals (VRX) recently announced that the the FDA has approved its Biologic License Application (BLA) for Siliq (brodalumab) injection the treatment of moderate-to-severe plaque psoriasis in adult patients.

            Arpita Dutt headshot

            Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ

            by Arpita Dutt

            The main news this week was an update from Merck (MRK) regarding its Alzheimer's disease drug.

              Arpita Dutt headshot

              Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback

              by Arpita Dutt

              Merck's (MRK) news represents the latest setback in the pharma and biotech sector's quest to find a treatment for Alzheimer's.

                Zacks Equity Research

                Lilly's Olumiant Gets Marketing Authorization in Europe

                by Zacks Equity Research

                Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.

                  Arpita Dutt headshot

                  Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi

                  by Arpita Dutt

                  Key highlights this week include earnings results from Allergan (AGN) and Glaxo, Sanofi's update regarding Praluent and Teva's ongoing woes.

                    Zacks Equity Research

                    Agilent (A) Announces Expanded Use of Diagnostic Assay (revised)

                    by Zacks Equity Research

                    Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 22C3 pharmDx.

                      Zacks Equity Research

                      AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales

                      by Zacks Equity Research

                      AstraZeneca PLC (AZN) reported fourth-quarter 2016 core earnings of $1.21 per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 51 cents. Core earnings also rose 9% year over year.

                        Zacks Equity Research

                        Agilent (A) Announces Expanded Use of Diagnostic Assay

                        by Zacks Equity Research

                        Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 28-8 22C3 pharmDx. This marks the company's effort to expand in the growing companion diagnostics market.

                          Zacks Equity Research

                          Allergan (AGN) Avycaz Label to Include New Phase III Data

                          by Zacks Equity Research

                          Allergan plc (AGN) announced that its supplemental new drug application (sNDA) for antibiotic Avycaz has been approved by the FDA. Allergan is looking to include new data from two phase III trials, RECAPTURE and REPRISE, in the drug???s label.

                            Zacks Equity Research

                            Ironwood/Astellas Report Positive Phase III Data on Linzess

                            by Zacks Equity Research

                            Ironwood (IRWD) and partner Astellas reported positive top-line data from a phase III study on Linzess in adults with chronic constipation.

                              Zacks Equity Research

                              AstraZeneca's Symbicort Granted Pediatric Exclusivity by FDA

                              by Zacks Equity Research

                              AstraZeneca (AZN) announced that the FDA has granted six months of pediatric exclusivity to its Symbicort inhalation aerosol.

                                Zacks Equity Research

                                Ironwood-Allergan Linzess Gets FDA Approval in Lower Dose

                                by Zacks Equity Research

                                Ironwood Pharmaceuticals, Inc. (IRWD) and partner Allergan plc (AGN) announced that the FDA has approved a lower dose strength of Linzess (linaclotide) ??? 72 mcg ??? for the treatment of adult patients with chronic idiopathic constipation (CIC).

                                  Zacks Equity Research

                                  Microsoft (MSFT) Beats on Q2 Earnings, Revenue Estimates

                                  by Zacks Equity Research

                                  Microsoft Corporation (MSFT) reported second-quarter fiscal 2017 earnings of 83 cents per share, which comfortably surpassed the Zacks Consensus Estimate of 79 cents.

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint

                                    by Arpita Dutt

                                    Key highlights this week include earnings reports from companies like Bristol-Myers (BMY) as well as the J&J-Actelion deal.

                                      Zacks Equity Research

                                      AstraZeneca Offers Update on Immuno-Oncology Program

                                      by Zacks Equity Research

                                      AstraZeneca (AZN) provided an update on its late-stage immuno-oncology program for first-line NSCLC.

                                        Zacks Equity Research

                                        Can AstraZeneca (AZN) Be a Solid Choice for Value Investors?

                                        by Zacks Equity Research

                                        Let's see if AstraZeneca (AZN) stock is a good choice for value-oriented investors right now from multiple angles.

                                          Arpita Dutt headshot

                                          The FDA Approved Fewer Drugs in 2016: Here's Why

                                          by Arpita Dutt

                                          Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View

                                            by Arpita Dutt

                                            Key highlights this week include a court injunction blocking sales of PCSK9 inhibitor Praluent and preliminary guidance from Allergan (AGN).

                                              Arpita Dutt headshot

                                              Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded

                                              by Arpita Dutt

                                              Key highlights this week include complete response letters from the FDA for a couple of companies with Cempra (CEMP) plunging to a 52-week low.

                                                Zacks Equity Research

                                                Pfizer Ibrance sNDA Accepted by FDA under Priority Review

                                                by Zacks Equity Research

                                                Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) to convert accelerated approval for its breast cancer drug, Ibrance, to regular approval was accepted by the FDA under priority review.

                                                  Zacks Equity Research

                                                  Clovis Scales 52-Week High on Early FDA Nod for Rubraca

                                                  by Zacks Equity Research

                                                  Shares of Clovis Oncology (CLVS) touched a 52-week high after the company gained accelerated FDA nod for its advanced ovarian cancer drug, Rubraca.